Press releases
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
- RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
- Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
- Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
- Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
More ▼
Key statistics
On Thursday, Lineage Cell Therapeutics Inc (LCTX:TLV) closed at 438.50, 29.73% above the 52 week low of 338.00 set on Dec 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 476.20 |
---|---|
High | 496.50 |
Low | 438.50 |
Bid | 438.50 |
Offer | 441.00 |
Previous close | 457.40 |
Average volume | 28.09k |
---|---|
Shares outstanding | 188.53m |
Free float | 180.75m |
P/E (TTM) | -- |
Market cap | 226.24m USD |
EPS (TTM) | -0.1243 USD |
Data delayed at least 20 minutes, as of Apr 18 2024 15:24 BST.
More ▼